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Augmentation of peritoneal clearance by dipyridamole. We performed
a double blind crossover trial in which dipyridamole was administered
to ten patients undergoing intermittent peritoneal dialysis at 2 liters!
hour (10 mm infusion, 30 mm intraperitoneal dwell of dialysate and 20
mm drainage of dialysate). After the patients received the drug for 3
days at a dose of 75 mg three times daily, peritoneal inulin clearance
increased by 1.2 mi/mm (P <0.05), and glucose absorption increased by
12.1 g (P < 0.05). The mechanism of the observed drug-induced effects
is unknown.
Augmentation de Ia clearance peritoneale par le dipyridamole. Nous
avons fajt une étude croisée en double insu au cours de laquelle le
dipyridamole a été administré a dix malades en dialyse péritonéale
intermittente avec 2 litres/heure (10 mm de perfusion, 30 mm de
stagnation intrapéritonéale du dialysat, et 20 mm de draInage du
dialysat). Après que les patients aient recu le médicament pendant troisjours a Ia dose de 75 mg trois fois par jour, Ia clearance péritonéale de
l'inuline s'est élevée de 1,2 mI/mn (P < 0,05) et l'absorption de glucose
s'est accrue de 12,1 g (P < 0,05). Le mécanisme de ces effets
médicamenteux est inconnu.
Peritoneal dialysis performed intermittently using hourly
exchanges of dialysate is less efficient in removing urea, creati-
nine, and inulin than hemodialysis performed using convention-
al dialyzers. Since the demonstration that intraperitoneal ad-
ministration of vasodilators could augment peritoneal dialysis
clearance rates, numerous investigators have sought methods
to pharmacologically alter clearances. Dipyridamole was sug-
gested as such an agent in two brief reports [1, 2]. Because of
these early reports we undertook a double blind trial in which
the efficacy of oral dipyridamole administered in a dose of 75
mg three times daily was tested against a placebo. Our results
demonstrate that dipyridamole administered in this fashion
augments peritoneal inulin clearance and glucose absorption
from dialysate.
Methods
Informed consent for the study was obtained from ten
volunteers, all of whom were undergoing outpatient intermit-
tent peritoneal dialysis on a Monday, Thursday or Tuesday,
Friday dialysis schedule for 20 hr twice weekly. The patients
were not receiving any dialysis between hospital visits.
The drug and placebo were supplied by Boehringer-Ingelheim
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(Ridgefield, Connecticut). The hospital pharmacy housed and
dispensed the drug or placebo to a nurse who was responsible
for teaching the patient the correct administration of the medi-
cation. The patients were instructed to take the medication at 10
AM., 2 P.M., and 6 P.M. Neither the physician nor any staff
member knew what medication the patient was ingesting. We
performed pill counts at each dialysis visit to check patient
compliance.
The study was balanced (by the pharmacist) so that five
patients received the drug and five patients received the place-
bo during the first period. The initial patient medication was
determined by the flip of a coin. The next patient received the
opposite to the first patient. The next patient's medication was
chosen by coin flip, and so on. Patients undergoing antihyper-
tensive therapy were maintained on medication throughout the
study.
At each dialysis outpatient visit during the study, clearance
measurements were performed over an 8-hr period. Following
the study period the patients completed their 20 hr of dialysis.
The study was performed as follows: On the first day of the
study the patient underwent a control measurement of peritone-
al clearance. At the next dialysis visit the patient was given an
8-day supply of either the drug or the placebo. Repeat peritone-
al clearance measurements were obtained at each outpatient
visit. The medication was then withdrawn for 7 days. After a 1-
week drug-free period the patient was given an 8-day supply of
the medication opposite to that taken during the first part of the
study. Peritoneal clearances were measured at each outpatient
visit for dialysis.
Patients were dialyzed using dialysate manufactured by Tra-
venol Laboratories, Inc., Deerfield, Illinois. All dialysate used
during the study exchanges contained 1.5% glucose. All dialy-
ses were carried out using a cycler machine and tubing (Ameri-
can Medical Products Corporation, Freehold, New Jersey). The
cycler machine was set to deliver a 2000-mi volume of dialysate.
The timers were adjusted to allow 40 mm for infusion and
intraperitoneal stay of dialysate and 20 mm for dialysate drain-
age. Prior to the study exchanges, four 1-hr exchanges were
performed. Following these exchanges, the patient and machine
were drained of dialysate. Eight 1-hr exchanges were then
performed mechanically. During this period, all dialysate efflu-
ent was collected into a reservoir. At the completion of the eight
exchanges, the pooled dialysate was thoroughly mixed and an
aliquot obtained for analysis. The start and completion times of
these eight hourly exchanges of dialysate and the pooled
volume were noted.
The volume of dialysate effluent was measured by weighing
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the dialysate on scales. The same scale was used for all studies.
Corrections were made for the tare weight of the dialysate
reservoir at each study. We assumed the specific gravity of
dialysate to be equal to that of water.
Blood was sampled at the start and close of the 8-hr study
period. Inulin (Arnar-Stone, Mt. Prospect, Illinois) was infused
2 hr prior to the study exchange period and reinfused at every
other dialysis during the study.
Creatinine in serum and dialysate was assayed following the
method of Hare [3]; urea was assayed using diacetyl-monox-
ime. Uric acid was assayed using autoanalyzer techniques [4].
Inulin in serum and dialysate was assayed by the method of
Walser modified to correct for glucose in dialy sate [5]. Protein
was measured in dialysate by trichloroacetic acid precipitation
[61. Sodium concentration in dialysate was measured using a
flame photometer (IL-Model 143).
Peritoneal clearances of creatinine, urea, and inulin were
calculated by multiplying the volume of dialysate effluent by the
concentration of dialysate effluent and dividing this product by
the plasma concentration multiplied by the time of the study
exchanges. The plasma concentration used in the calculations
was the average of values obtained at the start and close of the
8-hr period. Sodium losses into dialysate were calculated by
subtracting the amount infused from the amount in the dialysate
effluent (concentration multiplied by effluent volume).
The clearance measurements for each solute, the sodium lost
into dialysate, and protein lost in dialysate were analyzed. For
each variable studied, two primary comparisons were made: (1)
dipyridamole exchanges (N = 3) versus control and placebo
dialysis exchanges (N = 4) and (2) second and third dialyses
while the patient was ingesting dipyridamole (N = 2) versus
control and placebo dialyses (N = 4). The second comparison
was made to determine whether or not the effect of dipyrida-
mole was delayed.
A randomized complete block analysis of variance procedure
was carried out on all the data. The analysis of variance allows
mild departures from the assumptions of the test, particularly
when sample sizes are equal. The assumption of equality of
column variance in the analysis of variance procedure was
verified using Hartley's maximum F test. If this criteria was not
fulfilled Friedman's two-way analysis of variance procedure
was carried out [7—9].
To further investigate the nature of the differences observed
Bonferroni t statistics (two-sided) were calculated. For the
Bonferroni procedure, the overall probability of type I error (a)
is split between the two primary comparisons of interest on a
single variable. This method is recommended when the investi-
gator is interested in making a relatively small number of
comparisons among means and seeks to control the overall
error rate of the procedure.
Results
The results of the pill counts showed that five patients took
the study drug correctly. Each of the other five patients were
incorrect during the study period by one pill (too few ingested)
on one occasion. No patient was withdrawn from the study
because of an adverse reaction to medication.
Table 1 details the patient characteristics including age, sex,
etiology of uremia, mean blood pressure, antihypertensive
therapy, and mean serum chemistries over the study period.
Table 2 details the overall mean values for each period. The
comparisons of dipyridamole dialyses (three separate dialyses)
versus control and placebo dialyses (four separate dialyses),
and the second and third dialyses on dipyridamole (two sepa-
rate dialyses)—versus control and placebo (four separate dialy-
ses) were statistically significant only for the absorption of
glucose (P < 0.1, P < 0.05, respectively). The comparison of
dipyridamole second and third dialyses versus control and
placebo dialyses was significant for peritoneal inulin clearance
(P < 0.05) and at a lesser level of significance for peritoneal uric
acid clearance (P < 0.10).
Discussion
This method of performing peritoneal clearances provides
consistent results. These investigations demonstrate that dipyr-
idamole administered in a dose of 75 mg orally three times a day
augments peritoneal inulin clearance and glucose absorption
from dialysate. Studies with intraperitoneal vasodilators have
demonstrated increases in both small and large solute clear-
ances but greater percent changes with the larger solutes
suggesting a relatively greater effect of the vasodilator on
membrane area and/or permeability rather than effective perito-
neal blood flow [10]. In a previous study we showed glucose
absorption from dialysate increased during peritonitis [11]. We
attributed this to changes in peritoneal blood flow, area, or
permeability. Since the changes in peritoneal inulin clearance
are more likely related to peritoneal area and or permeability,
this study suggests that glucose absorption may be more
dependent on membrane area and/or permeability.
We were not able to demonstrate increases in peritoneal urea
and creatinine clearance. This may be due to the transient
vasodilatory effects of dipyridamole. The method of measuring
peritoneal clearances in this study, over an 8-hr period, would
hide short-term effects. Furthermore, our patients differed from
those reported in the past since we were not studying patients
with severe microvascular disease. In short-term studies
Maher, Hirszel, and Galen [1] could not demonstrate augmenta-
tion of peritoneal transport in patients who did not have
diseases that would have been expected to impair the peritoneal
circulation.
It is unclear as to why the observed changes in clearance
during the first dialysis on dipyridamole did not differ from the
control or placebo observations. The actual explanation is
unknown but it may have been a function of the time-course for
adaptation to drug administration. It is possible that the anti-
platelet effect of this drug was the most important influence in
augmenting inulin clearance by preventing stasis in the perito-
neal microcirculation. We have no data to support or contradict
this speculation.
An earlier study with few details using slightly greater doses
of dipyridamole (300 mg) suggested that dipyridamole may have
an effect upon peritoneal clearance after the medication was
discontinued [2]. Our study was not designed to observe a
delayed effect. If these changes in inulin clearance are sustained
over longer periods, this drug may be of some use for patients
undergoing intermittent peritoneal dialysis who have limited
residual renal function (less than 2.5 ml/min). Among patients
dialyzed for 20 hr twice weekly, an increase of 1 mI/mm of
inulin clearance would add 2.4 liters of clearance per week. The
drug may sufficiently augment peritoneal clearances to allow a
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Table 1. Patient characteristics
Serum chemistries
9 HT
10 CGN
31 M 193.0 87.5 3.3 25.3 0.5 5.6 0.1 16 0.8 11.9 + 0.2 140 6.8
59 M 170.2 76.8 + 2.1 12.6 0.27 5.2 0.04 17.6 0.7 7.8 + 0.3 160 + 6.3
Table 2. Overall means placebo versus dipyridamole
Total
Patient
no.
1
Diagnosis
DM
Age
years
56
Sex
F
Height
cm
BUN
mg
Creatinine
mg°'/
protein
g%
5.6 0.1
HTC
vol%
Uric acid
mg%
Glucose
mg%
152.4 63.1 3.0 14.5 1.1 15.4 0.6 7.1 0.4 217 22
2 CGN 31 M 161.3 64.1 3.3 24.1 0.5 6.1 0.1 22 0.7 7.6 0.2 105 13
3 CGN 58 M 177.8 96.8 4.5 19.7 0.8 6.3 0.1 20 + 0.6 8.7 0.4 146 1.8
4 HT 37 F 170.2 55.8 + 2.7 9.0 0.2 5.7 0.2 27 0.8 9.9 0.4 119 3.5
5 HT 44 F 132.1 45.3 1.7 13.7 0.4 5.2 0.1 20.4 1.3 6.2 0.2 147 + 8.8
6 HT 55 F 161.3 44.6 2.7 10.8 0.3 6.0 0.1 22 0.5 7.5 0.3 177 11.1
7 CIN 27 M 167.6 72.0 3.7 13.3 0.2 6.4 0.04 27 0.9 8.1 + 0.3 119 4.6
8 SLE 20 F 162.6 66.1 4.0 13.6 + 0.5 5.4 0.! 21 2.5 7.5 0.3 120 3.6
Control
3rd
Dialysis
1st
Dialysis
2nd
Dialysis
3rd
Dialysis
1st
Dialysis
Placebo
2nd
Dialysis
Dipyridamole
17.33
10.00
1.31
15.63
9.00
1.37
K urea, mi/mm
Mean value
N
Means SEM
13.33
10.00
1.10
17.12
10.00
2.72
15.32
10.00
1.38
15.93
10.00
1.78
14.06
10.00
1.33
K creatinine, mi/mm
Mean value
N
Means SEM
9.82
10.00
1.09
10.57
10.00
0.73
11.00
10.00
0.87
11.05
10.00
0.81
9.99
10.00
0.73
12.68
10.00
1.24
11.39
9.00
1.31
K uric, mi/mm
Mean value
N
Means SEM
7.60
10.00
0.93
8.98
10.00
1.11
8.23
10.00
1.09
9.62
10.00
1.25
8.70
10.00
0.94
10.65
10.00
1.42
l0.34h
9.00
1.64
K inulin, mi/mm
Mean value
N
Means SEM
4.11
10.00
0.65
4.76
10.00
0.70
3.58
10.00
0.34
4.69
10.00
0.62
3.88
10.00
0.47
5.69
10.00
0.53
5.2l
9.00
0.85
Protein loss, g
Mean value
N
Means SEM
4.96
10.00
1.11
5.58
10.00
0.74
5.29
10.00
0.75
5.57
10.00
0.80
5.38
10.00
0.54
7.33
10.00
0.90
7.32
9.00
1.47
Glucose ABS, g
Mean value
N
Means SEM
55.51
10.00
5.58
56.47
10.00
7.67
54.62
10.00
7.62
56.63
10.00
5.87
54.38°
10.00
3.5!
71.80
10.00
8.51
64.07a
9.00
7.29
Sodium loss, mEg
Mean value
N
Means SEM
28.42
10.00
15.98
44.63
10.00
13.04
80.00
10.00
15.97
32.79
10.00
48.74
64.09
10.00
10.41
43.45
10.00
26.17
72.52
9.00
26.43
Total volume, ml
Mean value
N
Means 5EM
16980.00
10.00
102.00
17180.00
10.00
153.30
17230.00
10.00
113.00
17170.00
10.00
176.00
17200.00
10.00
80.28
16890.00
10.00
133.71
17100.00
9.00
173.20
Time, mm
Mean value
N
Means SEM
484.00
10.00
2.96
483.00
10.00
2.13
485.40
10.00
2.93
483.50
10.00
6.69
483.50
10.00
2.36
483.00
10.00
3.00
480.00
9.00
0.00
Abbreviation: Glucose ABS, glucose absorption from dialysate.
° P < 0.05 2nd and 3rd dialysis dipyridamole vs. control and placebo.
b p < 0.10 2nd and 3rd dialysis dipyridamole vs. control and placebo.
° P < 0.10 all dipyridamole measurements (Ito 3) vs. control and placebo.
Augmentation of peritoneal clearance by dipyridamole 661
total body clearance of 30 liters per week of large molecular
weight solute (dialysate plus residual renal function). Both the
dialysis index postulated by Scribner, Farrell, and Milutinovic
1121 and a number of published observations [13—171 on nervous
system functions indicate the desirability of this degree of
middle molecule clearance.
In summary, dipyridamole significantly augments peritoneal
clearance of inulin when administered orally. The actual mecha-
nism of the observed drug-induced effects is unknown.
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Table 1. (Continued)
Mean wt
loss during
Mean weight study Mean BP Mean BP
prior dialysis exchanges predialysis postdialysis
kg kg mm Hg mm Hg Patient medications
47.3 0.3 0.5 0.1 116 4 117 5 Hydralazine, 50mg BID
57.0 0.3 —0.1 0.1 118 2 119 2 Hydralazine, 50mg BID; Propranolol, 80mg BID
75.7 0.3 0.4 0.1 111 5 113 4 Hydralazine, 100mg TID; Propranolol, 40mg TID
65.1 0.9 0.4 0.2 116 10 120 8 Prazosin, 10 mg BID; Propranolol, 40 mg BID
34.2 0.3 0.2 0.1 119 5 122 6 Hydralazine, 50mg TID; Propranolol, 80 mg TID
57.1 0.2 0.5 0.2 104 4 96 6 No medicines
53.6 0.1 0.3 0.1 106 5 102 4 a-Methyldopa, 250 mg BID
44.6 0.4 0.1 0.1 118 6 135 8 Propranolol, 160mg TID; Hydralazine, 100 mg BID;
Clonidine, 0.4 mg MD
87.4 0.6 0.2 0.2 134 4 142 3 Hydralazine, 100 mg TID; Propranolol, 80 mg TID
54.5 0.6 —0.1 0.2 85 2 81 2 No medicines
Abbreviations: DM, diabetes mellitus; CON, chronic glomerulonephritis; HT, hypertensive nephrosclerosis; CIN, chronic interstitial nephritis;
SLE, systemic lupus erythematosis.
